

Frederic Castinetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3261680/publications.pdf>

Version: 2024-02-01

177
papers

6,722
citations

61977

43
h-index

76898

74
g-index

200
all docs

200
docs citations

200
times ranked

5330
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
2	Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. <i>European Journal of Endocrinology</i> , 2015, 172, 195-204.	3.7	232
3	Ketoconazole in Cushing's Disease: Is It Worth a Try?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1623-1630.	3.6	231
4	Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4483-4488.	3.6	209
5	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	3.7	196
6	Genetics, diagnosis, management and future directions of research of pheochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456.	0.5	190
7	Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2007, 156, 91-98.	3.7	166
8	Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3400-3407.	3.6	164
9	Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. <i>European Journal of Endocrinology</i> , 2008, 158, 91-99.	3.7	158
10	Merits and pitfalls of mifepristone in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2009, 160, 1003-1010.	3.7	141
11	Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. <i>Molecular and Cellular Endocrinology</i> , 2010, 323, 4-19.	3.2	140
12	Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. <i>Lancet Oncology</i> , 2014, 15, 648-655.	10.7	137
13	Management of clinically non-functioning pituitary adenoma. <i>Annales D'Endocrinologie</i> , 2015, 76, 239-247.	1.4	136
14	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. <i>Clinical Endocrinology</i> , 2012, 76, 769-775.	2.4	125
15	Long-term prognosis of patients with pediatric pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2014, 21, 17-25.	3.1	121
16	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. <i>European Journal of Endocrinology</i> , 2017, 176, 769-777.	3.7	107
17	Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients. <i>World Neurosurgery</i> , 2016, 89, 442-453.	1.3	101
18	Role of stereotactic radiosurgery in the management of pituitary adenomas. <i>Nature Reviews Endocrinology</i> , 2010, 6, 214-223.	9.6	99

#	ARTICLE	IF	CITATIONS
19	Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1248-1257.	6.4	96
20	French Endocrine Society Guidance on endocrine side effects of immunotherapy. <i>Endocrine-Related Cancer</i> , 2019, 26, G1-G18.	3.1	95
21	Pituitary Stem Cell Update and Potential Implications for Treating Hypopituitarism. <i>Endocrine Reviews</i> , 2011, 32, 453-471.	20.1	86
22	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 213-220.	11.4	86
23	Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2007, 157, 271-277.	3.7	84
24	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2015, 22, T135-T145.	3.1	84
25	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , 2016, 23, 871-881.	3.1	82
26	Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. <i>JAMA Network Open</i> , 2019, 2, e198898.	5.9	80
27	Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms. <i>European Journal of Endocrinology</i> , 2011, 164, 457-465.	3.7	77
28	Cabergoline for Cushing's disease: a large retrospective multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 305-314.	3.7	77
29	A Novel Dysfunctional LHX4 Mutation with High Phenotypical Variability in Patients with Hypopituitarism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2790-2799.	3.6	73
30	Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. <i>Pituitary</i> , 2016, 19, 643-653.	2.9	70
31	MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. <i>European Journal of Endocrinology</i> , 2019, 181, R107-R118.	3.7	68
32	MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushing's syndrome during pregnancy: solved and unsolved questions. <i>European Journal of Endocrinology</i> , 2018, 178, R259-R266.	3.7	67
33	Aggressive pituitary tumours and pituitary carcinomas. <i>Nature Reviews Endocrinology</i> , 2021, 17, 671-684.	9.6	60
34	A comprehensive review on MEN2B. <i>Endocrine-Related Cancer</i> , 2018, 25, T29-T39.	3.1	58
35	Radiotherapy and radiosurgery in acromegaly. <i>Pituitary</i> , 2009, 12, 3-10.	2.9	56
36	18F-FDOPA PET/CT imaging of insulinoma revisited. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 409-418.	6.4	54

#	ARTICLE	IF	CITATIONS
37	Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?. <i>Endocrine-Related Cancer</i> , 2016, 23, R131-R142.	3.1	54
38	MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma. <i>European Journal of Endocrinology</i> , 2016, 174, R9-R18.	3.7	54
39	Medical Treatment of Cushing's Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone. <i>Neuroendocrinology</i> , 2010, 92, 125-130.	2.5	53
40	Pharmacokinetic Evidence for Suboptimal Treatment of Adrenal Insufficiency with Currently Available Hydrocortisone Tablets. <i>Clinical Pharmacokinetics</i> , 2010, 49, 455-463.	3.5	53
41	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2018, 25, T201-T219.	3.1	52
42	Persistent and recurrent hyperparathyroidism. <i>Updates in Surgery</i> , 2017, 69, 161-169.	2.0	50
43	DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. <i>European Journal of Endocrinology</i> , 2019, 181, R199-R209.	3.7	50
44	MECHANISMS IN ENDOCRINOLOGY: An update in the genetic aetiologies of combined pituitary hormone deficiency. <i>European Journal of Endocrinology</i> , 2016, 174, R239-R247.	3.7	49
45	Cushing's disease. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, 41.	2.7	46
46	Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France. <i>European Journal of Endocrinology</i> , 2018, 178, 447-458.	3.7	46
47	The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2012, 19, 295-299.	2.3	45
48	A Combined Dexamethasone Desmopressin Test as an Early Marker of Postsurgical Recurrence in Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1897-1903.	3.6	44
49	Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. <i>Clinical Endocrinology</i> , 2013, 78, 263-270.	2.4	44
50	Delayed diagnosis of Sheehan's syndrome in a developed country: a retrospective cohort study. <i>European Journal of Endocrinology</i> , 2013, 169, 431-438.	3.7	43
51	Preoperative imaging for focused parathyroidectomy: making a good strategy even better. <i>European Journal of Endocrinology</i> , 2015, 172, 519-526.	3.7	40
52	The risks of overlooking the diagnosis of secreting pituitary adenomas. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 135.	2.7	39
53	Approach to the Patient Treated with Steroidogenesis Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2114-2123.	3.6	39
54	SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook. <i>Annales D'Endocrinologie</i> , 2018, 79, 1-22.	1.4	38

#	ARTICLE	IF	CITATIONS
55	Combined pituitary hormone deficiency: current and future status. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1-12.	3.3	37
56	Three Novel Heterozygous Point Mutations of <i>NR3C1</i> Causing Glucocorticoid Resistance. <i>Human Mutation</i> , 2016, 37, 794-803.	2.5	34
57	Risk Profile of the RET A883F Germline Mutation: An International Collaborative Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2069-2074.	3.6	34
58	A conservative management is preferable in milder forms of pituitary tumor apoplexy. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 502-9.	3.3	32
59	Significant prevalence of NR3C1 mutations in incidentally discovered bilateral adrenal hyperplasia: results of the French MUTA-GR Study. <i>European Journal of Endocrinology</i> , 2018, 178, 411-423.	3.7	31
60	Non-functioning pituitary adenoma: When and how to operate? What pathologic criteria for typing?. <i>Annales D'Endocrinologie</i> , 2015, 76, 220-227.	1.4	30
61	A registry-based study of thyroid paraganglioma: histological and genetic characteristics. <i>Endocrine-Related Cancer</i> , 2015, 22, 191-204.	3.1	29
62	ISL1 Is Necessary for Maximal Thyrotrope Response to Hypothyroidism. <i>Molecular Endocrinology</i> , 2015, 29, 1510-1521.	3.7	28
63	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 278-282.	6.4	28
64	MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. <i>European Journal of Endocrinology</i> , 2017, 176, 323-328.	3.7	27
65	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1574-1582.	3.6	27
66	Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. <i>Annales D'Endocrinologie</i> , 2012, 73, 225-229.	1.4	26
67	Bilateral neck exploration in patients with primary hyperparathyroidism and discordant imaging results: a single-centre study. <i>European Journal of Endocrinology</i> , 2014, 170, 719-725.	3.7	26
68	Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. <i>Annales D'Endocrinologie</i> , 2018, 79, 591-595.	1.4	26
69	PITX2 AND PITX1 Regulate Thyrotroph Function and Response to Hypothyroidism. <i>Molecular Endocrinology</i> , 2011, 25, 1950-1960.	3.7	25
70	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. <i>Endocrine Pathology</i> , 2017, 28, 302-307.	9.0	25
71	Positron Emission Tomography Imaging in Medullary Thyroid Carcinoma: Time for Reappraisal?. <i>Thyroid</i> , 2021, 31, 151-155.	4.5	25
72	Lanreotide for the treatment of acromegaly. <i>Advances in Therapy</i> , 2009, 26, 600-612.	2.9	24

#	ARTICLE	IF	CITATIONS
73	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. <i>Clinical Endocrinology</i> , 2014, 81, 317-328.	2.4	24
74	Corepressors TLE1 and TLE3 Interact with HESX1 and PROP1. <i>Molecular Endocrinology</i> , 2010, 24, 754-765.	3.7	23
75	High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency. <i>American Journal of Human Genetics</i> , 2021, 108, 1526-1539.	6.2	23
76	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. <i>Annales D'Endocrinologie</i> , 2022, 83, 119-141.	1.4	23
77	Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. <i>Endocrine-Related Cancer</i> , 2018, 25, T15-T28.	3.1	22
78	Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort. <i>Clinical Endocrinology</i> , 2021, 94, 277-289.	2.4	22
79	Copy number variations alter methylation and parallel IGF2 overexpression in adrenal tumors. <i>Endocrine-Related Cancer</i> , 2015, 22, 953-967.	3.1	21
80	Early 18F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 686-695.	6.4	21
81	MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. <i>Endocrine</i> , 2020, 69, 496-503.	2.3	21
82	Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. <i>Pituitary</i> , 2018, 21, 615-623.	2.9	20
83	Acromegaly in Carney complex. <i>Pituitary</i> , 2019, 22, 456-466.	2.9	20
84	Pheochromocytoma surgery without systematic preoperative pharmacological preparation: insights from a referral tertiary center experience. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 728-735.	2.4	20
85	Postoperative follow-up of Cushing's disease using cortisol, desmopressin and coupled dexamethasone-desmopressin tests: a head-to-head comparison. <i>Clinical Endocrinology</i> , 2015, 83, 216-222.	2.4	19
86	The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations. <i>Endocrine-Related Cancer</i> , 2017, 24, L63-L67.	3.1	19
87	Active Cushing syndrome patients have increased ectopic fat deposition and bone marrow fat content compared to cured patients and healthy subjects: a pilot 1H-MRS study. <i>European Journal of Endocrinology</i> , 2018, 179, 307-317.	3.7	19
88	Medical management of Cushing's disease: When and how?. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13120.	2.6	19
89	GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency. <i>Hormone and Metabolic Research</i> , 2016, 48, 389-393.	1.5	18
90	Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2276-2277.	2.8	18

#	ARTICLE	IF	CITATIONS
91	Surgical indications for pituitary tumors during pregnancy: a literature review. <i>Pituitary</i> , 2020, 23, 189-199.	2.9	18
92	The risks of medical treatment of prolactinoma. <i>Annales D'Endocrinologie</i> , 2021, 82, 15-19.	1.4	18
93	Radiotherapy as a tool for the treatment of Cushing's disease. <i>European Journal of Endocrinology</i> , 2019, 180, D9-D18.	3.7	18
94	Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. <i>European Journal of Endocrinology</i> , 2009, 161, S11-S17.	3.7	17
95	Genetic causes of combined pituitary hormone deficiencies in humans. <i>Annales D'Endocrinologie</i> , 2012, 73, 53-55.	1.4	17
96	Heterozygous LHX3 mutations may lead to a mild phenotype of combined pituitary hormone deficiency. <i>European Journal of Human Genetics</i> , 2019, 27, 216-225.	2.8	17
97	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. <i>Endocrine Connections</i> , 2020, 9, 489-497.	1.9	17
98	Adrenal Myelolipoma: An Unusual Cause of Bilateral Highly 18F-FDG-Avid Adrenal Masses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2577-2578.	3.6	16
99	Patients lost to follow-up in acromegaly: results of the ACROSPECT study. <i>European Journal of Endocrinology</i> , 2014, 170, 791-797.	3.7	16
100	Lack of functional remission in Cushing's syndrome. <i>Endocrine</i> , 2018, 61, 518-525.	2.3	16
101	Does first-line surgery still have its place in the treatment of acromegaly?. <i>Annales D'Endocrinologie</i> , 2009, 70, 107-112.	1.4	15
102	Value of 123I/99mTc-sestamibi parathyroid scintigraphy with subtraction SPECT/CT in primary hyperparathyroidism for directing minimally invasive parathyroidectomy. <i>American Journal of Surgery</i> , 2019, 217, 108-113.	1.8	15
103	Identifying the Deleterious Effect of Rare LHX4 Allelic Variants, a Challenging Issue. <i>PLoS ONE</i> , 2015, 10, e0126648.	2.5	15
104	An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory. <i>Annales D'Endocrinologie</i> , 2015, 76, 1-8.	1.4	14
105	Contemporary review of large adrenal tumors in a tertiary referral center. <i>Anticancer Research</i> , 2014, 34, 2581-8.	1.1	14
106	Gamma Knife radiosurgery for hypothalamic hamartoma preserves endocrine functions. <i>Epilepsia</i> , 2017, 58, 72-76.	5.1	13
107	Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review. <i>Annales D'Endocrinologie</i> , 2019, 80, 122-127.	1.4	13
108	Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored. <i>Clinical Endocrinology</i> , 2023, 98, 629-630.	2.4	13

#	ARTICLE	IF	CITATIONS
109	Persistent cortisol response to desmopressin predicts recurrence of Cushing's disease in patients with post-operative corticotrophic insufficiency. <i>European Journal of Endocrinology</i> , 2020, 182, 489-498.	3.7	13
110	Group 4: Replacement therapy for adrenal insufficiency. <i>Annales D'Endocrinologie</i> , 2017, 78, 525-534.	1.4	12
111	Increased Risk of Persistent Glucose Disorders After Control of Acromegaly. <i>Journal of the Endocrine Society</i> , 2017, 1, 1531-1539.	0.2	12
112	IgG4 hypophysitis: Diagnosis and management. <i>Presse Medicale</i> , 2020, 49, 104016.	1.9	12
113	Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. <i>European Journal of Endocrinology</i> , 2021, 185, 863-873.	3.7	12
114	Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma. <i>BMC Cancer</i> , 2016, 16, 679.	2.6	11
115	Prospective evaluation of ⁶⁸ Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. <i>Clinical Endocrinology</i> , 2018, 89, 155-163.	2.4	11
116	Germinal defects of SDHx genes in patients with isolated pituitary adenoma. <i>European Journal of Endocrinology</i> , 2020, 183, 369-379.	3.7	11
117	Evaluation of an individualized education program in pituitary diseases: a pilot study. <i>European Journal of Endocrinology</i> , 2020, 183, 551-559.	3.7	11
118	Large Adrenal Incidentalomas Require a Dedicated Diagnostic Procedure. <i>Endocrine Practice</i> , 2019, 25, 669-677.	2.1	9
119	Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome. <i>Neurochirurgie</i> , 2021, 67, 556-563.	1.2	9
120	Controversies about the systematic preoperative pharmacological treatment before pheochromocytoma or paraganglioma surgery. <i>European Journal of Endocrinology</i> , 2022, 186, D17-D24.	3.7	9
121	Introduction to expert opinion on endocrine complications of new anticancer therapies. <i>Annales D'Endocrinologie</i> , 2018, 79, 535-538.	1.4	8
122	Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. <i>Endocrine</i> , 2020, 70, 134-142.	2.3	8
123	Radiation techniques in aggressive pituitary tumours and carcinomas. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 287-292.	5.7	8
124	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2726-2737.	3.6	8
125	Pituitary apoplexy after somatostatin analogue administration: coincidental or causative?. <i>Clinical Endocrinology</i> , 2014, 81, 471-473.	2.4	7
126	A monocentric experience of growth hormone replacement therapy in adult patients. <i>Annales D'Endocrinologie</i> , 2014, 75, 176-183.	1.4	7

#	ARTICLE	IF	CITATIONS
127	Transcranial approach in giant pituitary adenomas: results and outcome in a modern series. <i>Journal of Neurosurgical Sciences</i> , 2020, 64, 25-36.	0.6	7
128	Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat?. <i>Discovery Medicine</i> , 2010, 10, 107-11.	0.5	7
129	Current and Emerging Medical Therapies in Pituitary Tumors. <i>Journal of Clinical Medicine</i> , 2022, 11, 955.	2.4	7
130	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3313-e3320.	3.6	7
131	Lessons from monogenic causes of growth hormone deficiency. <i>Annales D'Endocrinologie</i> , 2017, 78, 77-79.	1.4	6
132	Clinical management of difficult to treat macroprolactinomas. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 179-192.	2.4	6
133	Risk stratification of adrenal masses by [¹⁸ F]FDG PET/CT: Changing tactics. <i>Clinical Endocrinology</i> , 2021, 94, 133-140.	2.4	6
134	Synergistic cortisol suppression by ketoconazole–osilodrostat combination therapy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, .	0.5	6
135	Impact of Cushing's syndrome on fertility and pregnancy. <i>Annales D'Endocrinologie</i> , 2022, 83, 188-190.	1.4	6
136	Pre-term birth in women exposed to Cushing's disease: the baby-cush study. <i>European Journal of Endocrinology</i> , 2021, 184, 469-476.	3.7	5
137	Long-term outcome of macroprolactinomas. <i>Annales D'Endocrinologie</i> , 2016, 77, 641-648.	1.4	4
138	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. <i>Langenbeck's Archives of Surgery</i> , 2017, 402, 787-798.	1.9	4
139	Characterization of adrenocortical tumors by 18F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?. <i>Surgical Oncology</i> , 2018, 27, 231-235.	1.6	4
140	An Open-Label, Analgesic Efficacy and Safety of Pituitary Radiosurgery for Patients With Opioid-Refractory Pain: Study Protocol for a Randomized Controlled Trial. <i>Neurosurgery</i> , 2018, 83, 146-153.	1.1	4
141	Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system. <i>Journal of Psychosocial Oncology</i> , 2018, 36, 624-634.	1.2	4
142	Tumor multifocality with vagus nerve involvement as a phenotypic marker of <i>SDHD</i> mutation in patients with head and neck paragangliomas: A ¹⁸ F-FDOPA PET/CT study. <i>Head and Neck</i> , 2019, 41, 1565-1571.	2.0	4
143	Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 239-240.	1.9	4
144	Commentary: The Impact of Insulin-Like Growth Factor Index and Biologically Effective Dose on Outcomes After Stereotactic Radiosurgery for Acromegaly: Cohort Study. <i>Neurosurgery</i> , 2020, 87, E301-E302.	1.1	4

#	ARTICLE	IF	CITATIONS
145	Adrenal Crisis May Occur Even In Patients With Asymptomatic Covid-19. <i>Endocrine Practice</i> , 2020, 26, 929-930.	2.1	4
146	Lack of delayed neurocognitive side effects of Gamma Knife radiosurgery in acromegaly: the Later-Ac study. <i>European Journal of Endocrinology</i> , 2022, 186, 37-44.	3.7	4
147	Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 385-387.	11.4	4
148	Gamma Knife for Cushing disease – time for a reappraisal?. <i>Nature Reviews Endocrinology</i> , 2017, 13, 628-629.	9.6	3
149	Letter to the Editor: “Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3557-3558.	3.6	3
150	Letter to the Editor: “Why We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRI” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5791-5792.	3.6	3
151	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A ¹⁸ F-DOPA PET/CT study in head and neck paragangliomas. <i>Clinical Endocrinology</i> , 2019, 91, 879-884.	2.4	3
152	Acromegaly in remission: a view from the partner. <i>European Journal of Endocrinology</i> , 2021, 185, K19-K23.	3.7	3
153	Familial hypocalciuric hypercalcemia: the challenge of diagnosis. <i>Endocrine</i> , 2022, 75, 646-649.	2.3	3
154	Radiosurgery: A Useful First-Line Treatment of Prolactinomas?. <i>World Neurosurgery</i> , 2010, 74, 103-104.	1.3	2
155	Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives. <i>Annales D'Endocrinologie</i> , 2021, 82, 52-58.	1.4	2
156	Women's perceptions of femininity after craniopharyngioma: a qualitative study. <i>Clinical Endocrinology</i> , 2021, 94, 880-887.	2.4	2
157	Congenital pituitary hormone deficiencies: role of LHX3/LHX4 genes. <i>Expert Review of Endocrinology and Metabolism</i> , 2008, 3, 751-760.	2.4	1
158	Disease of Adrenal Glands. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-2.	1.5	1
159	Combined Pituitary Hormone Deficiency. , 2016, , 177-194.		1
160	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. <i>Endocrinology</i> , 2018, , 93-128.	0.1	1
161	Genes important in the fetal development of the pituitary. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018, 1, 9-12.	1.4	1
162	Fluctuation analysis of postoperative secretory status in patients operated for acromegaly. <i>Annales D'Endocrinologie</i> , 2020, 81, 11-17.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. <i>Annales D'Endocrinologie</i> , 2020, 81, 39-43.	1.4	1
164	Coexistence of Endocrine Side Effects of Immunotherapy in Clinical Practice. <i>Endocrinology</i> , 2021, , 405-411.	0.1	1
165	Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism. <i>Journal of Clinical Lipidology</i> , 2021, 15, 712-723.	1.5	1
166	Letter to the Editor from Soghomonian et al.: "Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e434-e435.	3.6	1
167	Cushing's disease: role of preoperative and primary medical therapy. <i>Pituitary</i> , 0, , .	2.9	1
168	La chirurgie de première intention a-t-elle encore une place dans le traitement de l'acromégalie?. <i>Annales D'Endocrinologie</i> , 2009, 70, e23-e28.	1.4	0
169	Adenomi ipofisari. <i>EMC - AKOS - Trattato Di Medicina</i> , 2010, 12, 1-12.	0.0	0
170	Coexistence of Endocrine Side Effects of Immunotherapy in Clinical Practice. <i>Endocrinology</i> , 2021, , 1-7.	0.1	0
171	Glucocorticoid receptor antagonists: a therapeutic tool in Cushing's syndrome...to be handled with care. <i>Acta Endocrinologica</i> , 2010, 6, 91-94.	0.3	0
172	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. <i>Endocrinology</i> , 2018, , 1-37.	0.1	0
173	Prevention Medicine in Bilateral Pheochromocytoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
174	Pituitary Radiotherapy. , 2019, , 289-293.		0
175	Bilateral Adrenalectomy for Cushing Disease. , 2019, , 243-248.		0
176	Age and MEN2 outcome. <i>Aging</i> , 2019, 11, 3416-3417.	3.1	0
177	Diagnostic des phéochromocytomes et paragangliomes. <i>Oncologie</i> , 2020, , .	0.7	0